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Summary
Alzheimer’s disease (AD) is an age-associated disease. Mutations
in the amyloid precursor protein (APP) may be causative or
protective of AD. The presence of two functionally redundant
APP-like genes (APLP1/2) has made it difficult to unravel the
biological function of APP during aging. The nematode
Caenorhabditis elegans contains a single APP family member,
apl-1. Here, we assessed the function of APL-1 on C. elegans’
lifespan and found tissue-specific effects on lifespan by overexpression of APL-1. Overexpression of APL-1 in neurons causes
lifespan reduction, whereas overexpression of APL-1 in the
hypodermis causes lifespan extension by repressing the function
of the heterochronic transcription factor LIN-14 to preserve
youthfulness. APL-1 lifespan extension also requires signaling
through the FOXO transcription factor DAF-16, heat-shock factor
HSF-1, and vitamin D-like nuclear hormone receptor DAF-12. We
propose that reinforcing APL-1 expression in the hypodermis
preserves the regulation of heterochronic lin-14 gene network to
improve maintenance of somatic tissues via DAF-16/FOXO and
HSF-1 to promote healthy aging. Our work reveals a mechanistic
link of how a conserved APP-related protein modulates aging.

Key words: Alzheimer’s disease; APL-1; APP; FOXO transcription factor DAF-16; heat-shock factor HSF-1; heterochronic
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder affecting over
five million Americans and is the sixth leading cause of death (Alzheimer’s
Association 2015). The etiology of Alzheimer’s disease is unclear. The
highest risk factor for developing Alzheimer’s disease is age, whereby
96% of patients with AD develop the disease at 65 years or older
(Alzheimer’s Association 2015). The disease is characterized by the
deposition of amyloid plaques in brain tissue; the major component of the
plaques is the beta-amyloid peptide, a cleavage product of the amyloid
precursor protein (APP) (reviewed Selkoe & Hardy, 2016). Mutations in
APP and in genes that produce the presenilin enzymes that are part of the
c-secretase complex that cleaves APP are correlated with cases of familial
Alzheimer’s disease (Tanzi, 2012; reviewed Selkoe & Hardy, 2016).
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In mammals, the functional analysis of APP is complicated by the
presence of two APP-related proteins, APLP1 and APLP2 (reviewed
Shariati & De Strooper, 2013). Whereas knockouts of individual APP
family members are viable, double knockouts of APP and APLP2 or
APLP1 and APLP2 result in postnatal lethality (von Koch et al., 1997;
Herms et al., 2000, 2004), indicating an essential role for the APP family
and functional overlap among family members that is not dependent on
the beta-amyloid peptide. Knockout of the entire APP gene family results
not only in postnatal lethality, but also defects in neuronal migration and
type II lissencephaly (Weyer et al., 2011). Interestingly, duplication of the
APP gene has also been associated with families that develop early-onset
Alzheimer’s disease (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006;
Sleegers et al., 2006). More strikingly, patients with Down syndrome,
who have a trisomy of chromosome 21, have a high incidence of earlyonset Alzheimer’s disease (Korbel et al., 2009; reviewed in Shariati & De
Strooper, 2013). These findings suggest that higher levels of APP,
whether it be higher levels of the beta-amyloid peptide, the extracellular
or cytoplasmic fragments, and/or full-length APP, are correlated with
early-onset Alzheimer’s disease. However, the cellular functions of APP
and related proteins remain unclear.
The functions of genes correlated with Alzheimer’s disease, including
the presenilin genes, were first identified in genetic screens using the
nematode Caenorhabditis elegans [reviewed (Ewald & Li, 2010)]. We
have been examining the role of APL-1, the C. elegans orthologue of
mammalian APP. Similar to human APP, C. elegans APL-1 is a single
transmembrane-spanning protein with a large extracellular and a small
intracellular domain, both of which share sequence homology to human
APP (Daigle & Li, 1993). Analogous to the postnatal lethality of APP
family-knockout mice, loss of apl-1 in C. elegans results in a completely
penetrant larval lethality that is rescued by the reintroduction of either
full-length APL-1 or only the extracellular domain of APL-1 (Hornsten
et al., 2007). This finding was later extended to mammals, whereby
knockin of sAPPa rescued the postnatal lethality of the APP-APLP2double-knockout mice (Weyer et al., 2011). Furthermore, overexpression of APL-1 in C. elegans also causes an early developmental lethality,
but the lethality shows an incomplete penetrance that is correlated with
higher levels of APL-1 (Hornsten et al., 2007). Similarly, overexpression
of human or mouse APP in mice causes early developmental lethality in
the absence of amyloid plaques (Hsiao et al., 1995). This correlation
suggests that findings in C. elegans can provide insights into the
rudimentary conserved functions of APP (Ewald & Li, 2012).
Here, we examined the effects of overexpressing APL-1 during
adulthood on lifespan in C. elegans. Overexpressing APL-1 in neurons
shortens lifespan, whereas overexpressing APL-1 in hypodermis extends
lifespan. This lifespan extension is independent from longevity mediated
by reduced insulin/IGF-1 signaling (rIIS) or by reduced germ stem cell
numbers (rGSC). However, genes that are essential for rIIS and rGSC
longevity, such as the FOXO transcription factor DAF-16, heat-shock
factor HSF-1, and vitamin D-like nuclear hormone receptor DAF-12, are
required for APL-1-dependent longevity, suggesting that APL-1 interacts
with these genes in parallel to rIIS and rGSC. We found that hypodermal
APL-1 represses the transcriptional function of the heterochronic
transcription factor LIN-14, which has been shown to regulate longevity
through HSF-1 and DAF-16. Repressing LIN-14 during aging is required
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for hypodermal-expressed APL-1 to extend lifespan and higher levels of
LIN-14 are sufficient to abrogate the APL-1-induced longevity. These
findings suggest that APL-1 promotes longevity by regulating heterochronic processes.

Results
Ectopic expression of APL-1 during adulthood increases
lifespan
High levels of APL-1 cause larval lethality (Hornsten et al., 2007). To
bypass the developmental effects of APL-1 and to determine the role of
APL-1 during aging, we used transgenic animals (ynIs14) that have the
hsp-16.2 promoter fused with an apl-1 cDNA [Phsp-16.2::APL-1; (Ewald
et al., 2012a)] and induced APL-1 expression in adults in all tissues via
heat shock. Surprisingly, a single heat shock for 3.5 hours in day one
adults mildly increased lifespan (5%; Fig. 1a). Moreover, two hours of
heat shock administered every second day (Fig. 1b) or applying
moderate heat continuously (Fig. 1c; 25°C) robustly increased lifespan
(12–30%) of ynIs14 [Phsp-16.2::APL-1] animals compared to wild-type.
As a control, the same animals were assayed in parallel at 15 °C, a
temperature at which the hsp-16.2 promoter is not active, and no
change in lifespan was observed (Fig. 1d; Table S1). These results
suggest that inducing ubiquitous overexpression of APL-1 exclusively
during adulthood is sufficient to extend lifespan.

Overexpressing APL-1 in neurons shortens lifespan
The finding that ubiquitous adulthood expression of APL-1 increased
lifespan was surprising. To gain some mechanistic insights into how this
lifespan extension is mediated, we investigated in which tissue apl-1
expression is necessary for lifespan extension. C. elegans expresses apl-1
strongly in neurons throughout its life cycle (Hornsten et al., 2007) and
neurons regulate aging and longevity in a conserved spectrum of
animals, including C. elegans (Kenyon, 2010). To investigate whether
APL-1 expressed in neurons increases lifespan, we examined transgenic
animals carrying multicopy chromosomal arrays where apl-1 is driven by
different promoters: its endogenous promoter, the pan-neuronal rab-3
promoter that drives expression only in neurons, or the ceh-36 or mec-4
promoters that drive expression in a subset of neurons. Overexpression
of APL-1 with its own promoter, which includes strong expression in
neurons and glial cells ([Papl-1::apl-1::GFP]; Fig. 1e; Table S2), shortened
lifespan. Similarly, overexpressing APL-1 in all neurons with the rab-3
(Prab-3::APL-1::GFP; Fig. 1f; Table S2), or a subset of sensory neurons
(Pceh-36::APL-1::GFP; Fig. 1g and Pmec-4::APL-1::GFP; Fig. 1h;
Table S1), also shortened lifespan. Collectively, these results indicate
that neuronal overexpression of APL-1 shortens lifespan and is in stark
contrast to the extended lifespan induced by heat-shock overexpression
of APL-1 in all tissues, including neurons, in adults (Fig. 1). Therefore, we
hypothesized that expression of APL-1 in tissues other than neurons
must activate a protective pathway to circumvent the detrimental effects
of APL-1 expression in neurons.

Overexpression of APL-1 in multiple tissue types, including
neurons, increases lifespan
To identify the cells in which apl-1 expression counteracts the
detrimental effects of pan-neuronal apl-1 overexpression, we used the
snb-1 promoter, which drives expression strongly in neurons and somatic
gonad, but weakly in the hypodermis during adulthood (Fig. 2a; Ewald

et al., 2012a). APL-1 expression was tracked by fusion to green
fluorescent protein (GFP) at the C-terminus (Psnb-1::APL-1 cDNA::
GFP), which did not interfere with rescuing apl-1(null) larval lethality
(Hornsten et al., 2007). The most prominent expression in ynIs109 [Psnb1::apl-1 cDNA::GFP] transgenic animals was in neurons and somatic
gonad at 20°C (Fig. 2a). At 25°C, there were also high levels of APL-1
expression in the hypodermis (Fig. 2b). ynIs109 [Psnb-1::apl-1 cDNA::
GFP] lived 28% longer than control animals at 20°C (Fig. 2c); this
lifespan extension was not affected by the presence of the GFP tag, as
animals carrying a transgene without a GFP tag (ynIs12 [Psnb-1::apl-1
cDNA] and ynIs13 [Psnb-1::apl-1 cDNA]) showed a comparable lifespan
extension of 24% (average of eight individual trials) and 21% (average
of five individual trials) longer than wild-type, respectively (Table S2).
Knockdown of apl-1 by RNA interference (RNAi) suppressed the
increased longevity in ynIs13 [Psnb-1::apl-1 cDNA] animals (Fig. 2d;
Table S3), suggesting that the increased lifespan is specific to apl-1
expression. Furthermore, ynIs13 [Psnb-1::apl-1 cDNA] animals showed a
slowed aging process based on less accumulation of age-pigments and
enhanced muscle functions (Fig. 2e–f and S1). These results suggest that
overexpressing APL-1 in tissues other than neurons is beneficial for
extending health and lifespan.

Overexpression of functional APL-1 is required to increase
lifespan
There are several possible mechanisms by which Psnb-1::apl-1 cDNA
overexpression could increase lifespan. For example, lowering food
intake results in caloric restriction that increases lifespan (Kenyon, 2010).
However, pharyngeal pumping rates, a measure of food intake, were
unaltered in young transgenic APL-1 animals (Fig. S1c). Another hallmark
of caloric-restricted animals is lower fat content (Heestand et al., 2013).
The fat content of long-lived Psnb-1::APL-1 animals was not lower
compared to wild-type. Furthermore, the fat content of short-lived apl-1
(yn5) and Papl-1::APL-1 animals was also lower compared to wild-type
animals (Fig. S2), suggesting that the effects of APL-1 on fat content do
not correlate with its effect on lifespan and are, therefore, uncoupled
from longevity. Lifespan extension can also be induced in C. elegans by
mobilizing the unfolded protein response (UPR) (Taylor & Dillin, 2013).
APL-1 is a glycosylated, transmembrane protein that is presumably
processed in the endoplasmic reticulum (ER). Overexpression of APL-1
could overload the ER causing ER stress, thereby activating the UPR.
However, APL-1 overexpression does not cause ER stress or induce the
unfolded protein response (Fig. S3a–c). The increased lifespan, however,
was dependent on a functional APL-1 protein. The missense mutation
apl-1(yn32) causes an APL-1 E371K substitution that presumably
interferes with alpha secretase cleavage at the cell membrane. Expression of the apl-1(yn32) transgene did not rescue the apl-1(null) larval
lethality (Hornsten et al., 2007; Hoopes et al., 2010), suggesting that
APL-1(yn32) is not sufficient for rescue. Animals carrying the Psnb-1::
APL-1(E371K)::GFP transgene (ynEx236, 237, or 238) showed no
lifespan extension (Fig. 2h), suggesting that only functional APL-1 can
increase lifespan and that nonfunctional APL-1 has no adverse effects.
To further exclude that any protein structurally similar to APL-1 (e.g.,
human APP) driven by the snb-1 promoter could extend lifespan, we
measured the lifespan of animals carrying the Psnb-1::humanAPP
transgene, which had no effect on lifespan (Fig. 2c; Table S3). Human
APP is unable to rescue the apl-1(null) larval lethality (Hornsten et al.,
2007; Wiese et al., 2010), suggesting that human APP is not functional
in C. elegans. Taken together, these results suggest that overexpression
of functional APL-1 increases lifespan.
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Fig. 1 Overexpression of APL-1 in all
tissues during adulthood is sufficient to
increase lifespan. (a–d) Wild-type (N2) and
transgenic ynIs14 [Phsp-16.2::APL-1]
animals that express APL-1 driven by a
heat-shock promoter (Phsp-16.2) were
maintained at 15°C and shifted to different
temperatures as indicated in the
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early adulthood was sufficient to increase
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animals. (b) Repeated heat shocks every
other day during adulthood robustly
increased the lifespan of ynIs14 [Phsp16.2::APL-1] animals. (c) Elevated
temperatures were sufficient to drive APL-1
expression from hsp-16.2 promoter (not
shown; G. O’Connor, personal comm.) and
increased lifespan of ynIs14 [Phsp-16.2::
APL-1] animals. (d) At lower temperatures,
the hsp-16.2 promoter does not drive APL1 expression. The lifespan of ynIs14 [Phsp16.2::APL-1] animals was not extended. (e–
h) Overexpression of APL-1 with cellspecific promoters and its own promoter in
wild-type animals. (e) Pan-neuronal APL-1
overexpression of ynIs104 [Prab-3::APL-1::
GFP] animals resulted in a shortened
lifespan. (f) Transgenic ynEx214 [Pceh-36::
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shortened lifespan. (g) Transgenic ynIs113
[Pmec-4::APL-1::GFP] animals that
overexpress APL-1 in touch
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shortened lifespan. (h) Driving APL-1
overexpression from its endogenous
promoter results in higher APL-1 levels in
neurons, glia cells, and vulva muscles [Papl1::APL-1::GFP]. Transgenic ynIs79 [Papl-1::
APL-1::GFP] animals showed a shortened
lifespan. For (a–d) Lifespan assays were run
in parallel at the same time. P-value was
determined by log rank. Statistics and
additional lifespan data are in Table S1. For
(e–f). Lifespans are shown in cumulative
form. For (e–h) Schematic representation of
the expression pattern of APL-1 with
different promoters is from Ewald et al.
(2012a). Light green indicates neurons and
dark green indicates other tissues. P-value
was determined by log rank. Statistics and
additional lifespan data are in Tables S1 and
S2.
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APL-1 protein levels do not correlate with changes in lifespan
Another possibility for APL-1 lifespan effects is that levels of the APL-1
protein determine lifespan. However, levels of APL-1 protein did not
correlate with changes in lifespan, as ynIs79 [Papl-1::apl-1::GFP] animals
expressed the highest levels of APL-1::GFP, but showed a shortened
lifespan (Figs. 1e and S3d–f). Instead, we postulate that the increased

lifespan is context dependent; that is, where APL-1 is overexpressed
determines the APL-1 effect on longevity. Hence, as long as APL-1 is
overexpressed in the relevant tissues, lifespan will be increased. We
tested this model by mating short-lived ynIs86 [Papl-1::APL-1] transgenic
animals that show a 177-fold increase in APL-1 protein (Hornsten et al.,
2007) with long-lived ynIs12 [Psnb-1::APL-1] transgenic animals that
show a 71-fold increase in APL-1 protein (Hornsten et al., 2007). The
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Fig. 2 Overexpression of APL-1 in neurons and other tissues extends lifespan. Using the snb-1 promoter, apl-1 [Psnb-1::APL-1::GFP] is strongly expressed in neurons,
pharynx, and somatic gonad and more weakly expressed in hypodermal cells during adulthood at the normal cultivation temperature of 20°C. (a, b) Top panel: Schematic
representation of apl-1 expression. Middle panel: APL-1::GFP expression driven by the snb-1 promoter. Bottom panel: Corresponding bright field. (a) Day 3 adults lon-2
(e678) apl-1(yn10) ynEx109 [Psnb-1::APL-1::GFP] are shown with anterior to the left and ventral side down; animals were grown at 20°C. (b) At higher temperatures (25°C),
the hypodermal APL-1 expression becomes apparent in ynIs109 [Psnb-1::APL-1::GFP] animals. Day 1 ynIs109 [Psnb-1::APL-1::GFP] adults were shifted from
20°C to 25°C and day 3 adults are shown with anterior to the left and ventral side down. (c) Transgenic ynIs109 [Psnb-1::APL-1::GFP] showed extended lifespan compared to
jsIs1 [Psnb-1::SNB-1::GFP] control animals. Driving human APP with the snb-1 promoter had no effect on lifespan. P-value was determined by log rank. Statistics
are in Table S3. (d) Knockdown of apl-1 by RNAi mildly shortened lifespan of wild-type (N2) and suppressed longevity of ynIs13 [Psnb-1::APL-1] animals. P-value was
determined by log rank. Statistics are in Table S3. (e) Long-lived ynIs12 [Psnb-1::APL-1] animals showed lower lipofuscin (age-pigment) levels at days 8 and 11 compared
to wild-type (N2). Data were represented as mean  SEM P-values were determined by unpaired two-tailed t-test (***P < 0.0001). For scoring and additional strains,
see Fig. S1a,b. (f) Long-lived ynIs13 [Psnb-1::APL-1] animals showed pharyngeal pumping rates at day 11 compared to wild-type (N2). Data represented as mean  SEM
P-values were determined by unpaired two-tailed t-test. For additional strains and time points, see Fig. S1c–f. (g) Mutant or wild-type APL-1 expression driven with the snb-1
promoter shows similar GFP levels during adulthood at the normal cultivation temperature (20°C). Top panel shows head of a day 3 adult lon-2(e678) apl-1(yn10) ynEx109
[Psnb-1::APL-1::GFP] animal with bright field on the left and corresponding GFP on the right. Bottom panel shows head of a day 3 adult ynEx236 [Psnb-1::APL-1(E371K)::
GFP] animal with bright field on the left and corresponding GFP on the right. (h) Transgenic animals that express a mutated APL-1(E371K) with the snb-1 promoter failed
to increase lifespan. Lines 1, 2, and 3 are ynEx236, ynEx237, and ynEx238, respectively. Statistics and additional lifespan data are in Table S1. (i) The double transgenic
ynIs12; ynIs86 animals, which carry two transgenes [Psnb-1::APL-1] and [Papl-1::APL-1], that drive APL-1 overexpression with its endogenous and snb-1 promoter,
respectively, showed increased lifespan. Statistics and additional lifespan data are in Tables S2 and S3.

resultant double transgenic strain showed a 199-fold increase in APL-1
levels compared to wild-type and was long-lived (Figs. 2i and S3d–e;
Table S3), demonstrating that the tissue in which apl-1 is expressed and
not the overall levels of APL-1 protein determines lifespan.

22% increase in lifespan and fully recapitulated the increase in longevity
seen in ynIs109 [Psnb-1::APL-1::GFP] animals (Fig 3b; Tables S1 and S4).
Hence, apl-1 overexpression in the hypodermis is critical for the APL-1dependent increase in lifespan.

Overexpression of APL-1 in hypodermal cells is sufficient to
increase lifespan

Overexpression of the extracellular domain of APL-1 is
sufficient to affect lifespan in a tissue-dependent manner

The long-lived ynIs109 [Psnb-1::APL-1::GFP] transgenic animals showed
prominent APL-1::GFP expression in neurons and the somatic gonad and
slightly weaker expression in the hypodermis (Fig. 2). The somatic gonad
has previously been shown to regulate lifespan via hormonal signaling
(Kenyon, 2010; Antebi, 2013). However, driving APL-1 expression
exclusively in the somatic gonad or in combination with neuronal APL-1
did not alter lifespan (Fig. 3a; Table S1). Lastly, we tested whether
hypodermal APL-1 expression could increase lifespan. We generated
transgenic animals that overexpress APL-1 exclusively in the hypodermis
(ynEx234 [Pcol-10::APL-1::GFP]). These transgenic lines showed an 11–

Similar to other APP family members, C. elegans APL-1 is a single
transmembrane-spanning protein with a large extracellular and a small
intracellular domain (Fig. 4a; Daigle & Li, 1993). The extracellular domain
of APL-1 (APL-1EXT), which is analogous to sAPL-1, is necessary and
sufficient to rescue the apl-1(null) lethality (Hornsten et al., 2007; Wiese
et al., 2010). Furthermore, the apl-1(yn5) allele completely lacks the
genomic region encoding the transmembrane and intracellular domains,
but is viable (Hornsten et al., 2007). To determine whether the
extracellular domain of APL-1 modulates lifespan, we examined apl-1
(yn5) mutants and transgenic animals that overexpress the extracellular
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domain of APL-1 (APL-1EXT) in a wild-type background. Both apl-1(yn5)
mutants and transgenic animals that overexpressed APL-1EXT from the
apl-1 promoter (ynIs71 [Papl-1::APL-1EXT]) showed shortened lifespans,
similar to the shortened lifespan when full-length APL-1 was overexpressed (Fig. 4b,c). By contrast, when APL-1EXT expression was driven
with the snb-1 promoter (ynIs105 [Psnb-1::APL-1EXT]), the animals
showed an extended lifespan compared to wild-type (Fig. 4d). Furthermore, expressing APL-1EXT in the hypodermis increased lifespan
(ynEx241 [Pcol-10::APL-1EXT]; Fig. 4e; Table S1). By contrast, expressing
APL-1EXT in the hypodermis is not sufficient to rescue the lethality seen
in apl-1(yn10) null alleles (0/3 lines rescued). Thus, the extracellular
domain of APL-1 modulates aging in a tissue-specific manner.

Extended lifespan of Psnb-1::APL-1 transgenic animals
requires daf-16 and daf-12 activity
We have previously demonstrated that overexpression of APL-1EXT
slows developmental progression via the FOXO transcription factor DAF16 and vitamin D-like nuclear hormone receptor DAF-12 VDR (Ewald
et al., 2012b). Both DAF-16 FOXO and DAF-12 VDR activities are

30

Fig. 4 The extracellular domain of APL-1
modulates lifespan depending on the
tissues in which it is expressed. (a)
Schematic of genomic region (left panel)
and model of APL-1 cleavage (right panel).
a = alpha secretase, HSPG = heparan
sulfate proteoglycans, N-Glyc. = Nglycosylation. The extracellular domain of
APL-1 has two potential HS binding
domains. (b) Transgenic ynIs71 [Papl-1::
APL-1EXT] animals that overexpress the
extracellular domain of APL-1 (APL-1EXT)
driven by its endogenous promoter showed
a shortened lifespan. (c) Transgenic ynIs105
[Psnb-1::APL-1EXT] animals that
overexpress the extracellular domain of
APL-1 (APL-1EXT) driven by the snb-1
promoter showed an extended lifespan. (d)
apl-1(yn5) mutants, which contain higher
levels of the extracellular domain of APL-1
compared to wild-type (Fig. S3d,e), showed
a shortened lifespan. (e) Transgenic
ynEx241 [Pcol-10::APL-1EXT] animals that
overexpress the extracellular domain of
APL-1 (APL-1EXT) in the hypodermis
showed an extended lifespan. For (b-d)
Lifespans are shown in cumulative form.
Statistics and additional lifespan data are in
Table S2.

essential to mobilize mechanisms that extend lifespan (Kenyon, 2010;
Antebi, 2013). Thus, we investigated whether overexpression of APL-1
modulates lifespan via daf-16 and daf-12. The longevity of ynIs12 [Psnb1::apl-1 cDNA], ynIs109 [Psnb-1::apl-1 cDNA::GFP], and ynIs105 [Psnb1::APL-1EXT] was completely abolished in daf-16(null) and daf-12
mutants (Fig. 5a,b; Tables S1 and S3), suggesting that activity of DAF16 FOXO and DAF-12 VDR is required to mediate longevity by APL-1
overexpression. Furthermore, we assessed whether other known transcriptional regulators essential for extending lifespan are required for the
Psnb-1::APL-1EXT-mediated longevity (Fig. S3g). We found that hsf-1
(heat-shock factor 1) was completely and skn-1 (Nrf1,2,3 homologue)
was partially required for the lifespan extension of ynIs105 [Psnb-1::APL1EXT] animals (Table S3).
Many reproductive and metabolic disruptions increase lifespan. For
instance, loss of germline stem cells, such as with a glp-1(e2141)
mutation, or reducing insulin/IGF-1 signaling, such as with a daf-2
(e1370) mutation, extends lifespan via daf-16 and/or daf-12 (Kenyon,
2010). We investigated how APL-1EXT released from hypodermal cells
acts to increase lifespan. When germline stem cells were removed with a
glp-1 mutation, the longevity of ynIs105 [Psnb-1::APL-1EXT] animals was
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further extended (Fig. 5c; Table S3). In addition, RNAi of kri-1 and tcer-1,
genes required for the glp-1 mutant-mediated longevity, did not
suppress the longevity of ynIs105 [Psnb-1::APL-1EXT] animals
(Table S3), suggesting that APL-1 overexpression increases lifespan in a
pathway independent of the longevity pathway mediated by the loss of
germline stem cells. Similarly, the longevity of ynIs12 [Psnb-1::APL-1] was
further extended when insulin/IGF-1 signaling was reduced (rIIs; Fig. 5d;
Tables S1 and S3), again suggesting that the APL-1-mediated longevity is
independent of the reduced rIIs-mediated longevity pathway. Furthermore, mRNA levels of sod-3 and gst-4, genes that are transcriptionally
upregulated under reduced insulin/IGF-1 conditions (Murphy et al.,
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Fig. 5 The APL-1-induced longevity
requires DAF-16 and DAF-12. (a) The
longevity of transgenic ynIs105 [Psnb-1::
APL-1EXT] animals was suppressed by a null
mutation in daf-16, which encodes a FOXO
transcription factor. (b) The longevity of
transgenic ynIs105 [Psnb-1::APL-1EXT]
animals was suppressed by a mutation in
daf-12, which encodes a vitamin D-like
nuclear hormone receptor (VDR). (c) The
longevity of transgenic ynIs105 [Psnb-1::
APL-1EXT] animals was additive to the
longevity of animals with reduced germ
stem cell numbers (glp-1(e2141)). (d) The
longevity of transgenic ynIs12 [Psnb-1::APL1] animals was additive to the longevity of
animals with reduced Insulin/IGF-1 signaling
(daf-2(e1370)). (e–f) mRNA levels of
canonical DAF-16 target genes (sod-3 and
gst-4) under reduced insulin/IGF-1
conditions are not altered in animals that
overexpress APL-1. Three independent trials
of N > 1000 of mixed-stage animals per
trial were analyzed. Data are represented as
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2003; Ewald et al., 2015), were not altered when APL-1 was overexpressed (Fig. 5e–f). Taken together, these results suggest that hypodermal APL-1 interacts with DAF-16 and DAF-12 in pathways parallel to the
insulin/IGF-1 and germline stem cells pathways to increase lifespan.

Hypodermal APL-1 longevity is mediated by the
heterochronic transcription factor LIN-14
Recently, daf-16 FOXO and daf-12 VDR activities have been shown to
form a regulatory circuit with lin-14 to regulate longevity (Shen et al.,
2012). LIN-14 is a heterochronic transcription factor that controls the
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transition from the first to second larval stage during development
(Hristova et al., 2005). At the first larval stage (L1), LIN-14 protein levels
are high, thereby regulating genes that retain cells in the L1 stage
(Ambros & Horvitz, 1984, 1987). During the first to second larval stage
transition and later in development, the microRNA lin-4 prevents lin-14
translation by an RNA–RNA interaction (Lee et al., 1993). However, this
inhibition is gradually lost during aging, when lin-4 miRNA levels
decrease, thereby allowing LIN-14 protein levels to increase (Boehm &
~ez-Ventoso et al., 2006; Iban
~ ez-Ventoso & Driscoll,
Slack, 2005; Ib
an
2009). Interestingly, knocking down lin-14 levels by RNAi in adults or by
a temperature-sensitive lin-14 mutation during the larval-to-adult
transition is sufficient to increase lifespan via daf-16 FOXO and heatshock factor HSF-1 (Boehm & Slack, 2005). Thus, we investigated
whether the Psnb-1::APL-1 transgene expression mediates lifespan
extension by acting in the same pathway as LIN-14. The Psnb-1::APL-1
transgene-mediated longevity was not further increased by either RNAi
knockdown of lin-14 or by a lin-14(n179) mutation (Fig. 6a,b; Table S4).
Furthermore, RNAi knockdown of lin-14 was not additive to the
longevity of hypodermal APL-1 (ynEx234 [Pcol-10::APL-1::GFP; Fig. 6a;
Table S4], suggesting that hypodermal APL-1 and lin-14 act in the same
pathway to mediate longevity. Conversely, overexpressing LIN-14
protein in ynIs109 [Psnb-1::APL-1::GFP] abolished the Psnb-1::APL-1mediated longevity (Fig. 6b; Table S4), suggesting that APL-1 activity
represses the activity of LIN-14. Interestingly, increasing LIN-14 protein
levels in ynIs109 [Psnb-1::APL-1::GFP] animals results in a shortened
lifespan (Fig. 6b; Table S4). We hypothesize that repression of lin-14
mobilizes a protective response against the detrimental effects of
neuronal APL-1. We tested this hypothesis by increasing levels of LIN-14
in hypodermal APL-1 overexpression lines and found the suppression of
hypodermal APL-1-induced longevity, but no lifespan reduction compared to wild-type (Fig. 6c; Table S4). To determine whether hypodermal
APL-1 represses LIN-14 activity during aging, we collected mRNA of
postreproductive 8-day-old adult animals and measured the expression
levels of three canonical LIN-14 target genes, cyp-13, ins-33, and
C15C7.5. During the first larval stage when LIN-14 expression is high,
C15C7.5 is upregulated, while cyp-13 and ins-33 are downregulated
(Hristova et al., 2005). If APL-1 acts to repress LIN-14 activity, we
predicted that genes that are normally repressed by LIN-14 are
upregulated and genes that are normally upregulated by LIN-14 are
downregulated. Consistent with this hypothesis, cyp-13 and ins-33 were
upregulated and C15C7.5 gene was downregulated in ynIs109 [Psnb-1::
APL-1::GFP] animals compared to wild-type at day 8 of adulthood
(Fig. 6d), suggesting that hypodermal APL-1 is repressing LIN-14 activity
during aging. Taken together, we propose that hypodermal APL-1
represses LIN-14 levels during aging, which prolongs lifespan via hsf-1,
daf-12, and daf-16 (Fig. 6e).

Discussion
Mammalian APP is expressed in all tissue types (Tanzi et al., 1987), but
an unresolved question remains as to whether APP has a similar function
in all cell types or whether its functions are context dependent. As this
question is difficult to address in mammalian systems, we turned to
C. elegans where the use of cell-specific promoters is routine. Because
higher levels of APP have been correlated with Alzheimer’s disease and
Down syndrome, we asked whether levels of APL-1, the C. elegans APPrelated protein, have an effect on lifespan. Longevity in any organism is
the result of a combination of environmental effects and genetic factors.
C. elegans is constantly monitoring its surroundings and integrating this
information to regulate its metabolic and reproductive processes, which

ultimately determine the animal’s lifespan. Several tissues, such as
neurons, intestine, and gonad, have been implicated in regulating
lifespan in C. elegans (Kenyon, 2010). For instance, ablation of certain
amphidial sensory neurons can either lead to lifespan enhancement or
reduction; similarly, ablation of germline precursor cells leads to an
increased lifespan. These effects on lifespan are dependent in DAF-16
FOXO and DAF-12 VDR activity (Kenyon, 2010).
The effects of APL-1 overexpression on lifespan were context
dependent (Fig. 6e). Overexpressing apl-1 under its own promoter
caused accelerated aging and lifespan reduction. By contrast, ubiquitous
expression of apl-1 in adults caused lifespan extension. These results
suggest that where APL-1 is expressed impacts its effects on lifespan.
Because apl-1 expression in neurons, but not in hypodermal cells, is
sufficient to rescue the lethality of apl-1 null mutants, we hypothesized
that neuronal apl-1 expression was responsible for lifespan extension.
Unexpectedly, the converse results were found; namely, apl-1 overexpression only in neurons led to lifespan reduction. However, apl-1
overexpression in hypodermal tissue is critical for lifespan extension and
this lifespan extension is additive to the longevity induced by reduction in
insulin signaling or by the removal of germline stem cells. Furthermore,
we showed that expression of only the extracellular domain of APL-1 in
these tissues was sufficient to cause these lifespan effects and lifespan
extension is dependent on the activity of daf-16 FOXO and DAF-12 VDR.
By contrast, hypodermal expression of apl-1 or APL-1EXT is not sufficient
to rescue the lethality of apl-1 null mutants. Hence, the target of
neuronal release of sAPL-1 vs. hypodermal release of sAPL-1 appears
different. We hypothesize that migration of sAPL-1 is limited or confined
by its local environment. For instance, sAPL-1 has two heparin binding
domains (Fig. 4a), suggesting that the secreted APL-1 could interact
locally with the extracellular matrix to limit its diffusion. Deleting the
heparin binding domains of APL-1EXT resulted in a failure to rescue the
apl-1 null lethality (unpublished observation). Furthermore, overexpression of APL-1EXT lacking the heparin binding domains had no effect on
lifespan (Table S3), suggesting that interactions between sAPL-1 and the
extracellular matrix are essential for APL-1 function. Collectively, these
results indicate that APL-1 has multiple functions: expression of apl-1 in
neurons is required for viability, whereas expression of apl-1 in
hypodermal cells regulates longevity.
The lifespan effects due to apl-1 overexpression were not dependent
on downregulating metabolic pathways via insulin/IGF-1 signaling or
decreasing numbers of germline stem cells, but were influenced by the
heterochronic pathway. apl-1 has been previously linked to the let-7
microRNA and heterochronic regulatory network (Niwa et al., 2008),
which is composed of a regulatory cascade of protein regulators and
microRNAs (miRNAs) that coordinate the onset of stereotypical stagespecific developmental events (Ambros & Horvitz, 1987; Rougvie &
Moss, 2013). In particular, while levels of the LIN-14 transcription factor
are negatively regulated by the lin-4 miRNA to allow transition from the
first to the second larval stage (Lee et al., 1993), levels of lin-4 miRNA
decrease with age, allowing LIN-14 levels to increase, thereby limiting
~ez-Ventoso & Driscoll, 2009). We propose
the lifespan of C. elegans (Iban
that hypodermal apl-1 expression represses levels of LIN-14, resulting in
an increased lifespan relative to wild-type animals (Fig. 6e).
In C. elegans, maintenance of somatic tissues is lost during the first
day of adulthood (Labbadia & Morimoto, 2014). This is consistent with
the disposable soma theory that predicts that resources are allocated
from the somatic tissue to the germ line (Kirkwood & Holliday, 1979),
which happens when animals become reproductive during the L4-toadult transition. Interestingly, using a transcriptional reporter of the
endogenous promoter of apl-1 expressing GFP, apl-1 has been shown
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by Niwa and colleagues to be transiently expressed under the control
of let-7 miRNA network during the L4-to-adult transition in the
hypodermal seam cells (Niwa et al., 2008). However, this hypodermal
APL-1 expression is lost in adulthood and we show here that ectopically

expressing APL-1 during adulthood in the hypodermis leads to
increased health- and lifespan. We speculate that reinforcing APL-1
expression in the hypodermis is a reprogramming of developmental
networks via heterochronic LIN-14 to improve the maintenance of
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somatic tissues via DAF-16/FOXO and HSF-1 that leads to improved
organismal lifespan. The implication of an APP-related protein functioning in a miRNA and heterochronic gene network to promote
healthy aging might point toward a possible entry to use miRNAs as a
therapeutic intervention to modulate age-related consequences of APP
function.

Material and methods

RNA interference
RNAi clones were picked from the Ahringer or Vidal libraries. Cultures
were grown overnight in LB with 12.5 lg/mL tetracycline and 100 lg/
mL ampicillin, diluted to an OD600 of 1, and induced with 1 mM IPTG.
This culture was seeded onto NGM agar plates containing tetracycline,
ampicillin, and additional IPTG. Empty vector (EV) plasmid pL4440 was
used as control.

Strains

Lifespan assays

Caenorhabditis elegans strains were grown and maintained on MYOB or
NGM plates containing OP50 Escherichia coli bacteria at 20°C, unless
noted. All mutations are described in WormBase (www.wormbase.org)
and include LGI: daf-16(mu86); LGII: tcer-1(tm1452); LGIII: daf-2(e1370),
glp-1(e2141); LGX: daf-12(m20), lon-2(e678), apl-1(yn5 and yn10)
(Hornsten et al., 2007), dpy-8(e130), and lin-14(n179). Construction of
the APL-1 transgenes and the resulting transgenic lines are described
(Hornsten et al., 2007) and (Ewald et al., 2012a), except as indicated.
Nonintegrated transgenic lines used were ynEx30 [Papl-1::APL-1, sur-5::
GFP], ynEx65 [Psnb-1::APL-1(yn5)(cDNA), sur-5::GFP], ynEx93 [Prab-3::
APL-1(cDNA)::GFP, pRF4 rol-6(su1006gf)], ynEx109 [Psnb-1::APL-1
(cDNA)::GFP], ynEx212 [Pmec-4::APL-1 (cDNA)::GFP, Pmyo-3::mCherry],
ynEx213 [Pmec-4::APL-1 (cDNA)::GFP, Pmyo-3::mCherry], ynEx214
[Pceh-36::APL-1 (cDNA)::GFP, Pmyo-3::mCherry], ynEx236 [Psnb-1::
APL-1(E371K)::GFP, Pmyo-3::mCherry], ynEx237 [Psnb-1::APL-1
(E371K)::GFP, Pmyo-3::mCherry], ynEx238 [Psnb-1::APL-1(E371K)::GFP,
Pmyo-3::mCherry], ynEx242 [Pfln-1::APL-1::GFP, Pmyo-3::mCherry]),
ynEx243 [Pfln-1::APL-1::GFP, Pmyo-3::mCherry], ynEx244 [Pfln-1::APL1::GFP, Pmyo-3::mCherry], ynEx234 [Pcol-10::APL-1 (cDNA)::GFP, Pmyo3::mCherry], ynEx235 [Pcol-10::APL-1 (cDNA)::GFP, Pmyo-3::mCherry],
ynEx239 [Pcol-10::APL-1EXT (cDNA), sur-5::GFP], ynEx240 [Pcol-10::
APL-1EXT (cDNA), sur-5::GFP], and ynEx241 [Pcol-10::APL-1EXT (cDNA),
sur-5::GFP]. Integrated transgenic lines used were ynIs100 [Papl-1::APL-1
(yn32), pRF4 rol-6(su1006gf)], ynIs106 [Papl-1::APL-1(yn32 yn5)], ynIs14
[Phsp-16.2::APL-1 (cDNA), lin-15B(+)],Pmyo-2::GFP), ynIs113 [Pmec-4::
APL-1 (cDNA)::GFP, Pmyo-3::mCherry], jsIs1 [Psnb-1:: SNB-1::GFP, pRF4
rol-6(su1006gf)], dvEx371 [Psnb-1::humanAPP751 (cDNA), Pmtl-2::GFP],
dvEx372 [Psnb-1::humanAPP751 (cDNA), Pmtl-2::GFP], zaIs2 [LIN-14::
GFP, rol-6(su1006)] (Hong et al., 2000; Olsson-Carter & Slack, 2010);
LGI: ynIs109 [Psnb-1::APL-1(cDNA)::GFP]; LGII: ynIs105 [Psnb-1::APL-1
(yn5)(cDNA), sur-5::GFP]; LGIII: jsIs682 [Prab-3::GFP::RAB-3], ynIs12
[Psnb-1::APL-1(cDNA), lin-15B(+)]; LGIV: vsIs13 (lin-11::pes-10::GFP, lin15(+)), ynIs104 [Prab-3::APL-1(cDNA)::GFP, Pmyo-2::GFP], zIs356 [Pdaf16::DAF-16::GFP, pRF4 rol-6(su1006gf)]; LGV: ynIs13 [Psnb-1::APL-1
(cDNA), lin-15B(+)], ynIs71 [Papl-1::APL-1(yn5), sur-5::GFP], ynIs79 [Papl1::APL-1::GFP], ynIs100 [Papl-1::APL-1(yn32)::GFP, pRF4 rol-6
(su1006gf)]; and LGX: dvIs62 (Psnb-1::humanTDP-43, Pmtl-2::GFP),
ynIs86 [Papl-1::APL-1, sur-5::GFP], ynIs91 [Prab-3::APL-1 (cDNA), pRF4
rol-6(su1006gf)], ynIs107 [Papl-1::APL-1(yn32 D342C/S362C)::GFP,
Pmyo-2::GFP], and ynIs108 [Papl-1::APL-1(DH, DE2)::GFP; sur-5::GFP].

Because our laboratory uses a different growing media (MYOB) than
other laboratories, which normally use (NGM), and wild-type shows a
different mean lifespan of 14 days on MYOB vs. 21 days on NGM
(Keightley & Caballero, 1997), we performed most experiments on
both media as indicated (Tables S1–S4). Lifespan results were similar on
MYOB or on NGM. Note that the wild-type N2 var. Bristol strain has
been maintained for many generations in different laboratories and can
have mean lifespans ranging from 12 to 17 days at 20°C (Gems &
Riddle, 2000). N2 animals from another laboratory (kindly provided by
Cathy Savage-Dunn) showed a similar lifespan as our N2 stock on
MYOB plates in four independent trials (198/398 animals). To determine whether the laboratory N2 animals had a longer lifespan on NGM
plates, N2 animals were grown on MYOB until the L4 stage and then
transferred onto NGM plates for lifespan analysis; these animals
showed a mean lifespan of 18.62  0.47 days (60/111 animals). These
results indicate that the N2 mean lifespan of 14 days reported here is
due to the different composition of the MYOB plates compared to
NGM plates.
For all lifespan trials, NGM: L4 animals were picked onto fresh OP50
plates, and then day one adults were placed on either OP50 or RNAi
plates containing 50 lM 5-fluoro-20 -deoxyuridine (FUdR), unless otherwise indicated, as described in Ewald et al. (2015). All lifespan trials on
MYOB were performed without FUdR. All strains were grown for at least
two generations at 20°C, except for daf-2(e1370) and glp-1(e2141)
animals, which were raised at 15°C. All adult lifespans [except glp-1
(e2141)] were measured starting from the L4 stage at 20°C. Animals
carrying the temperature-sensitive glp-1(e2141) allele and appropriate
control animals were shifted from 15°C to 25°C at the L1 stage and
lifespan assays were performed at 25°C.

Generating transgene constructs
To eliminate the heparin sulfate binding domains (H) of APL-1, the
coding region for REEGSPCKWTHSVR, corresponding to amino acids 96–
106, was deleted from the pAPL-1DE2::GFP construct (Hornsten et al.,
2007), which already had the heparin binding domain within E2 deleted,
to generate the Papl-1::APL-1(DH, DE2)::GFP construct with both
heparin sulfate binding domains deleted.

Pharyngeal pumping assays
The pharyngeal pumping rate was determined by the number of pumps
per 20 s; measurements were only taken when worms were on bacteria
and pumped at a constant rate without any pauses as described (Ewald
et al., 2012b).

Autofluorescence assays
L4 animals were picked and scored at appropriate times. Animals were
placed on an agar pad containing a drop of 10 mM NaN3. Pictures
were taken with a Hamamatsu ORCA-ER digital camera on a Zeiss
Axioplan microscope. The area directly behind the last bulb of the
pharynx was photographed using Openlab 3.1.3 software (Improvision,
Coventry, United Kingdom) with the same settings for all animals and
conditions. The autofluorescence intensities were derived by selecting a
defined area of the worm in the pictures and computing the ‘mean
gray value’ by ImageJ software (NIH).
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Western blot analysis
Preparations of animal lysates and Western blots were performed as
described (Hornsten et al., 2007). Protein levels were normalized to
levels of actin (~40 kDa) for each strain, so that similar amounts of
total protein were loaded for each strain. For each blot, the blot was
first probed with an actin monoclonal antibody (JLA20 at 1:2000;
Developmental Studies Hybridoma Bank, Iowa City, Iowa, United
States; secondary antibody anti-mouse-goat-HRP at 1:1000), washed
three times with TAE, and then re-probed with an anti-APL-1 antiserum
against the extracellular domain of APL-1 (Hornsten et al., 2007).
Relative protein levels were determined by relative intensity to wildtype (N2) using NIH Image J Gel analyzer.

Quantitative real-time polymerase chain reaction (qRT-PCR)
assays
Mixed-stage animals were harvested (>1000 animals; three independent
trials; Figs. 5e–f and S3b,c,f). For adulthood qRT-PCR: one-day adults
were placed on OP50 NGM FUdR plates at 20°C and 8 days later, 200
worms were harvested (Fig. 6d). RNA was isolated with Trizol (TRI
REAGENT; Sigma, St. Louis, Missouri, United States), DNase-treated, and
cleaned over a column (RNA Clean & ConcentratorTM; ZYMO Research,
Irvine, California, United States). First-strand cDNA was synthesized in
duplicate from each sample (Invitrogen, Carlsbad, California, United
States, SuperScript III). SYBR green was used to perform qRT-PCR
(Applied Biosystems 7900, Thermo Fisher Scientific Inc., Waltham,
Massachusetts, USA). For each primer set, a standard curve from
genomic DNA accompanied the duplicate cDNA samples (Ewald et al.,
2015). mRNA levels relative to N2 control were determined by
normalizing to the number of worms and the geometric mean of three
reference genes [cdc-42, pmp-3, and Y45F10D.4 (Hoogewijs et al.,
2008)]. At least two biological replicates were examined for each
sample. For statistical analysis, one-sample t-test, two-tailed, hypothetical mean of 1 was used for comparison using Prism 4.0a software
(GraphPad, La Jolla, California, United States).

Fat quantification
Fixed Oil Red O (ORO) staining: Worms were synchronized by
hypochlorite treatment and day 1 adult worms were fixed. ORO staining
of fixed animals and quantification was performed.
Triglyceride quantification: Mixed-stage worms were collected and
prepared as described. Triglyceride levels were measured with the
Triglyceride Colorimetric Assay Kit (#10010303; Cayman Chemical, Ann
Arbor, MI, USA) and normalized to protein levels using BCA protein
assay (Pierce Biotechnology, Thermo Fisher Scientific Inc., Waltham,
Massachusetts, USA).
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